uso 22326
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Disease Types: Breast Cancer Research
Eligibility Requirements:
-Women and Men, >18 years at the time of screening (or per national guidelines) -Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol. -Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy --Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor) -Eastern Cooperative Oncology Group (ECOG) performance status of < 1 -Adequate organ and marrow function
Available at:
- Chesapeake
- Hampton (CarePlex)
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Virginia Beach (Princess Anne)
- Williamsburg